🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Hester Biosciences Limited HESTERBIO NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.hester.in
Company Profile ↓
₹2,384.90
+33.36% 1Y
Mkt Cap₹2,028.80 Cr
P/E36.46
P/B6.01
Div. Yield0.52%
52W High₹2,534.00
52W Low₹1,253.66
Book Value₹423.46
EPS (TTM)₹65.40

Company Overview

Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India and internationally. It operates through two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutics, nutritional supplements, and specialised formulations to enhance animal wellness and productivity. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, grooming products, and anti-infective formulations; and healthcare products, such as immune boosters, gut health enhancers, farm hygiene, vitamins, minerals, and specialty feed supplements for critical needs comprising disease prevention, growth, and nutritional balance. Additionally, the company provides Silvectant, a hydrogen peroxide and silver nitrate solution for disinfection of poultry sheds; Hestbac, a probiotic supplement to control pathogenic bacteria; Hestflora, a combined probiotic and prebiotic formulation that supports gut health and performance; AmmoStop, a probiotic blend for odour control and respiratory comfort in poultry farms. It also offers INACTIVATED H9N2 vaccine for low pathogenic avian influenza; ICEFT RTU, a ceftiofur formulation for uterine and bacterial infections; and Inomilk Gel, an oral calcium supplement, as well as operates diagnostic labs for poultry. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Mehsana, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 15.4%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 15.8%.

Consistent Profit Growth

Net profit has compounded at 27.8% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 36.5, below the sector median of 40.0.

Healthy Margins

Maintains a net profit margin of 16.7%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹332.60 Cr (+6.9% YoY); net profit ₹55.64 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +6.9%, earnings +102.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 7.7%, profit CAGR 27.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:7.72%
1 Year:6.91%

Compounded Profit Growth

5 Years:27.85%
1 Year:102.41%

Stock Price Performance

1 Year:+33.36%
6 Months:+50.65%
3 Months:+61.54%
1 Month:+15.90%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 88% of range
₹1,253.66 ₹2,534.00
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)63.80 · Neutral
Price Performance
1M+15.90%
3M+61.54%
6M+50.65%
1Y+33.36%
Valuation vs Sector

P/E of 36.46 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 27.8% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
36.46
Industry PE
39.97
Forward P/E est.
18.23
PEG Ratio
-
Book Value
₹423.46
Price to Book
6.01
P/S
6.48
EV/EBITDA
28.91
Dividend Yield
0.52%

Growth (CAGR)

Revenue 5Y
7.72%
Profit 5Y
27.85%
Revenue (YoY)
6.91%
Earnings (YoY)
102.41%

Profitability & Returns

ROCE
15.84%
ROE
15.45%
ROA
8.21%
Profit Margin
16.73%
Op Margin
23.19%
Gross Margin
71.63%
EPS (Latest Qtr)
₹19.45
EPS (TTM)
₹65.40

Balance Sheet & Liquidity

Debt/Equity
0.54
Quick Ratio
0.89
Current Ratio
1.37
Debt
₹194.79 Cr
Total Assets
₹677.94 Cr
Current Assets
₹208.56 Cr
Working Capital
₹56.08 Cr

Ownership

Promoter Holding
68.79%
Chg in Prom Hold
15.06%
FII / Inst Holding
0.27%
Chg in FII Hold
-0.11%

Financial Snapshot

Enterprise Value
₹2,028.80 Cr
Total Revenue (TTM)
₹332.60 Cr
EBITDA
₹102.13 Cr
Free Cash Flow
₹46.31 Cr
Operating Cash Flow
₹64.14 Cr
Shares Outstanding
₹85.07 L
Gross Margin
71.63%
Payout Ratio
10.70%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 HESTERBIO Hester Biosciences Limited NSEPHARMA 2,384.90 36.46 ₹2,028.80 Cr 0.52% 15.84% 15.45% 7.72% 27.85%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 67.00 Cr88.00 Cr70.00 Cr67.00 Cr79.00 Cr82.00 Cr84.00 Cr-81.92 Cr84.11 Cr70.97 Cr77.42 Cr100.11 Cr
Cost of Revenue --------20.74 Cr22.46 Cr19.32 Cr20.73 Cr19.45 Cr
Gross Profit --------61.18 Cr61.64 Cr51.65 Cr56.69 Cr80.66 Cr
Operating Expenses 56.00 Cr73.00 Cr57.00 Cr57.00 Cr63.00 Cr65.00 Cr65.00 Cr-46.18 Cr43.01 Cr44.29 Cr43.33 Cr52.24 Cr
Operating Income 7.00 Cr9.00 Cr9.00 Cr6.00 Cr12.00 Cr14.00 Cr15.00 Cr-15.01 Cr18.63 Cr7.36 Cr13.36 Cr28.42 Cr
EBITDA 12.00 Cr14.00 Cr13.00 Cr10.00 Cr16.00 Cr18.00 Cr19.00 Cr-13.54 Cr26.18 Cr23.60 Cr19.78 Cr36.10 Cr
Interest Expense 1.00 Cr3.00 Cr8.00 Cr2.00 Cr7.00 Cr5.00 Cr6.00 Cr-5.62 Cr1.81 Cr2.21 Cr1.82 Cr5.09 Cr
Pretax Income 8.00 Cr9.00 Cr7.00 Cr6.00 Cr10.00 Cr11.00 Cr12.00 Cr-3.75 Cr20.19 Cr17.04 Cr13.52 Cr25.09 Cr
Tax Provision 2.56 Cr2.25 Cr2.80 Cr2.22 Cr3.50 Cr3.19 Cr3.48 Cr-2.20 Cr2.89 Cr2.71 Cr4.21 Cr8.54 Cr
Net Income 6.00 Cr7.00 Cr4.00 Cr4.00 Cr6.00 Cr7.00 Cr8.00 Cr-1.29 Cr16.44 Cr14.45 Cr8.77 Cr15.98 Cr
Diluted EPS 5.336.904.814.685.827.459.64-1.8220.3316.8510.9419.45

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 90.00 Cr101.00 Cr123.00 Cr136.00 Cr178.00 Cr183.00 Cr214.00 Cr-266.09 Cr304.55 Cr311.10 Cr332.60 Cr
Cost of Revenue --------85.82 Cr110.18 Cr102.63 Cr94.36 Cr
Gross Profit --------180.27 Cr194.36 Cr208.47 Cr238.24 Cr
Operating Expenses 64.00 Cr67.00 Cr82.00 Cr89.00 Cr110.00 Cr128.00 Cr146.00 Cr-138.71 Cr152.08 Cr163.23 Cr161.11 Cr
Operating Income 19.00 Cr28.00 Cr34.00 Cr37.00 Cr56.00 Cr42.00 Cr56.00 Cr-41.56 Cr42.28 Cr45.24 Cr77.13 Cr
EBITDA 25.00 Cr34.00 Cr41.00 Cr47.00 Cr68.00 Cr55.00 Cr69.00 Cr-66.00 Cr58.25 Cr64.71 Cr102.13 Cr
Interest Expense 5.00 Cr4.00 Cr4.00 Cr4.00 Cr7.00 Cr7.00 Cr7.00 Cr-5.15 Cr9.12 Cr8.34 Cr7.42 Cr
Pretax Income 18.00 Cr25.00 Cr31.00 Cr36.00 Cr57.00 Cr41.00 Cr50.00 Cr-40.15 Cr31.95 Cr39.57 Cr75.84 Cr
Tax Provision 4.68 Cr5.75 Cr8.06 Cr12.96 Cr15.96 Cr10.25 Cr15.50 Cr-12.12 Cr10.79 Cr10.74 Cr18.35 Cr
Net Income 13.00 Cr19.00 Cr23.00 Cr23.00 Cr41.00 Cr31.00 Cr35.00 Cr-26.63 Cr18.89 Cr27.49 Cr55.64 Cr
Diluted EPS 15.9922.5727.6830.1248.8734.2940.4746.2231.3022.2032.3165.40

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 160.00 Cr186.00 Cr213.00 Cr244.00 Cr299.00 Cr387.00 Cr411.00 Cr-669.97 Cr662.35 Cr653.38 Cr677.94 Cr
Current Assets --------227.59 Cr214.62 Cr195.17 Cr208.56 Cr
Cash & Equivalents --------12.67 Cr12.31 Cr5.59 Cr2.77 Cr
Inventory --------84.81 Cr75.58 Cr70.38 Cr72.53 Cr
Receivables --------79.63 Cr78.64 Cr73.18 Cr95.36 Cr
Total Liabilities --------381.42 Cr359.47 Cr326.73 Cr310.15 Cr
Current Liabilities --------148.70 Cr105.47 Cr125.18 Cr152.48 Cr
Long Term Debt --------184.81 Cr182.09 Cr133.37 Cr89.96 Cr
Total Debt 55.00 Cr59.00 Cr66.00 Cr69.00 Cr90.00 Cr121.00 Cr110.00 Cr-274.15 Cr244.38 Cr213.25 Cr194.79 Cr
Total Equity 85.00 Cr102.00 Cr122.00 Cr141.00 Cr178.00 Cr202.00 Cr229.00 Cr-279.73 Cr291.79 Cr314.25 Cr360.24 Cr
Shares Outstanding --------85.07 L85.07 L85.07 L85.07 L

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 20.00 Cr19.00 Cr35.00 Cr38.00 Cr47.00 Cr37.00 Cr58.00 Cr-23.60 Cr48.18 Cr64.51 Cr64.14 Cr
Investing Cash Flow -21.00 Cr-13.00 Cr-30.00 Cr-26.00 Cr-21.00 Cr-73.00 Cr-42.00 Cr--77.00 Cr-22.61 Cr-19.00 Cr-2.87 Cr
Financing Cash Flow 7.00 Cr-7.00 Cr2.00 Cr-11.00 Cr3.00 Cr19.00 Cr-18.00 Cr-41.76 Cr-26.09 Cr-51.72 Cr-48.79 Cr
Capital Expenditure -19.00 Cr-14.00 Cr-30.00 Cr-23.00 Cr-23.00 Cr-73.00 Cr-41.00 Cr--77.76 Cr-24.40 Cr-20.59 Cr-17.83 Cr
Free Cash Flow 1.00 Cr5.00 Cr5.00 Cr15.00 Cr24.00 Cr-36.00 Cr17.00 Cr--54.17 Cr23.79 Cr43.92 Cr46.31 Cr
Net Change in Cash 5.00 Cr-1.00 Cr6.00 Cr1.00 Cr28.00 Cr-17.00 Cr-2.00 Cr--11.64 Cr-51.60 L-6.21 Cr12.48 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------67.7%63.8%67.0%71.6%
Operating Margin % 21.1%27.7%27.6%27.2%31.5%23.0%26.2%-15.6%13.9%14.5%23.2%
Net Margin % 14.4%18.8%18.7%16.9%23.0%16.9%16.4%-10.0%6.2%8.8%16.7%
ROE % 15.3%18.6%18.9%16.3%23.0%15.3%15.3%-9.5%6.5%8.7%15.4%
ROCE % --------8.0%7.6%8.6%14.7%

Shareholding Pattern

Insiders
68.79%
Institutions
0.27%
Public Float
0.86%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for HESTERBIO

Google News Fri, 10 Jul 2026

Hester Biosciences Limited (NSE:HESTERBIO) Looks Like A Good Stock, And It's Going Ex-Dividend Soon - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxQX3M3amtaMkQyUVU1NFF1UnJlaVRLWVZ4dTNPZEYwMlZBZ1lLdXdZQjlhUk9SRG5QUVVFT2FpNWdGejRHZEozX082Vl9oSTI2QV9wQ05LT0VFYkVCU2pobDh2elFveHotMVRMcmFqU25oNzJ5ODlkdnZMUm1YaDNSb0N3R0ludlNkaWc0an…

Google News hu, 09 Jul 2026

HESTERBIO Surges as Firm Sells Remaining 11% Stake in Texas Lifesciences for ₹2.3 Crore - Sahi

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOYjJfQTFzU19SS1U5SXM2c2wxVk1ldmI5RURrSk9jUTJHdVlVTU1JV3V5bUd4R3ZzTDVKOHNxUUpVQnhiQ3N0bU8ydVZjcUQ3MDJCWmNoeV9lYkItVW9rLUF1c3JWbi1MdVIzWHJxTG9JelAyR0wwek0wY1hZd1Y3X3JJemU1bHFFVmNKd3…

Google News Mon, 13 Jul 2026

Hester Biosciences Sets ₹11-per-share Dividend - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQQTRHSTMyeGlTOXhSSlZCOFNBTjdTU0lBVmlpTjhaMHNyMV9YZDlrQi1TY3liQzhiX3dRdWhLUUhlemNvYUVtOGZaNUpRTVN6dzc4eU5XMUZBNTFJN0IzaGk5al9EY0VxZy11Z2pBS2NkcDBoQ1NzNTNobjcyOWx0MTZhMHl0WWZYbGxPNT…

Google News Mon, 13 Jul 2026

Volume Gainers, July 13: CLC Industries, Hester Bio, Just Dial Lead - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxORkkxek1IRmtlbldnU19kMGs4YXpSMXBJVzdCUXVacWJaaFZRdXktWWdaRGNNc1ZMdUpHdEQ4UTF6U0lFY05XMEJ3eVVrVlhpU1ROMGY3VlMwb0M4UWx5Qk41eHRoT3Z1a051X1ctSmZJZXJlM3FWZ090b1dBNGFoeDVhM0FNb1ZjYUhLZW…

Google News Fri, 15 May 2026

Hester Bio Standalone March 2026 Net Sales at Rs 93.71 crore, up 22.23% Y-o-Y - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxQWmVyLVBWTFJpS0k1aFlJalFYWU56OUhQU29CbmQ3RmNfRVM5ZVhTMlp3M3pPdUVEdHY0LTFDUmxIZFJqVFFBVFNMT0dORWs5U1hUYWNkUHJxY0JnYWpGUF9CdVg4bjFIUXJqbG1KLWMxZjdZWURVdENyOUkyNFN2Vy1hTFROX2pwT25NY0…

Google News Fri, 15 May 2026

Hester Biosciences Q4 Results: Stock jumps 14% after profit growth, strong operating performance - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNbElfa0lHaHBrWDFYejJKdEg0SmpaTVI0UWtJd1AzN3Q0OW5Wb1ZYNUhSWmVmVHR1RTZOcHlxdWdmLUxwbVBLd01QbDVqOURmY09ZNE1FdVA4NnJLb19hdnlGZjdtUXBYVTNuaVpqcFRKdTJKN2k1WWdvVUxjMHp3aVNEZTZybmVmdFVtaW…

HESTERBIO — Frequently Asked Questions

What is the current share price of Hester Biosciences Limited (HESTERBIO)?

As of 2026-07-15 09:52 IST, Hester Biosciences Limited (HESTERBIO) trades at ₹2,384.90 on NSE. Its 52-week range is ₹1,253.66 to ₹2,534.00.

What is the market capitalisation of HESTERBIO?

Hester Biosciences Limited (HESTERBIO) has a market capitalisation of ₹2,028.80 Cr on NSE.

What is the P/E ratio of HESTERBIO?

HESTERBIO trades at a trailing price-to-earnings (P/E) ratio of 36.46. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 6.01.

Does HESTERBIO pay a dividend?

Hester Biosciences Limited (HESTERBIO) currently offers a dividend yield of 0.52%.

What is the return on equity (ROE) of HESTERBIO?

HESTERBIO has a return on equity (ROE) of 15.45%. Its return on capital employed (ROCE) is 15.84%.

Is HESTERBIO a good stock to buy?

This page provides a data-driven analysis of Hester Biosciences Limited (HESTERBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space